Cancer News Review
Cancer News Review – Sniffing Out Cancer, New Melanoma Drug, Genes for Aggressive Cancer and Smoking-Related Bladder Cancer
This month, Kimmel Cancer Center director William Nelson reviewed four major cancer research stories ranging from pets that sniff out cancer to a reminder of… Read More »Cancer News Review – Sniffing Out Cancer, New Melanoma Drug, Genes for Aggressive Cancer and Smoking-Related Bladder Cancer
This month's Cancer News Review podcast with Kimmel Cancer Center director Bill Nelson begins with updates on the field of head and neck cancer in light of the encouraging news that actor Michael Douglas' cancer is in remission. Nelson says that there is an emerging story in oropharyngeal cancers (those that are in the back of the throat, tongue, soft palate and tonsils). An increasing number of these cancers are associated with certain strains of the human papillomavirus (HPV), the same virus that causes cervical cancer. Patients with HPV-associated head and neck cancers fare better than patients whose cancers are causes by alcohol or tobacco use. He says the molecular details of why this infection causes cancers and why these patients fare better is still not understood.
Three stories top the list of major developments in cancer research during the past month. Listen to these topics discussed in the most recent Cancer News Review podcast.
First, to treat or not to treat is the question for low-risk prostate cancer. Whether to give aggressive treatments for low-risk cancer contained within the prostate is a controversy that many experts in the field still debate. Prostate cancer expert and Kimmel Cancer Center director William Nelson reviews a study analyzing how treatment decisions for these cancers are made and how quality of life expectations are communicated. He says the current problem is that screening, which has helped decrease mortality from prostate cancer, has identified some men who could live their entire lives with prostate cancer but die of other causes. He believes there are certain groups of men who should consider active surveillance programs to carefully monitor low-risk, organ-confined prostate cancer.